Clinical trial
Role of Autologous Mononuclear Cell Therapy in Muscular Dystrophy
NCT02241928 is registered in ClinicalTrials.gov with Neurogen Brain and Spine Institute as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Role of Autologous Mononuclear Cell Therapy in Muscular Dystrophy
- Lead sponsor
- Neurogen Brain and Spine Institute
- Phase
- Phase 1
- Overall status
- Withdrawn
- Start date
- January 31, 2009
- Completion date
- May 31, 2019
- Enrollment
- 0 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
muscular dystrophy